Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to 85713.23%.

  • HeartSciences' EBITDA Margin fell 874012100.0% to 85713.23% in Q4 2025 from the same period last year, while for Oct 2025 it was 2314.37%, marking a year-over-year decrease of 36381400.0%. This contributed to the annual value of 192013.13% for FY2025, which is 1581111400.0% down from last year.
  • Latest data reveals that HeartSciences reported EBITDA Margin of 85713.23% as of Q4 2025, which was down 874012100.0% from 98637.84% recorded in Q3 2025.
  • Over the past 5 years, HeartSciences' EBITDA Margin peaked at 9214.54% during Q3 2024, and registered a low of 98637.84% during Q3 2025.
  • For the 5-year period, HeartSciences' EBITDA Margin averaged around 30478.53%, with its median value being 25266.6% (2024).
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 567670000bps in 2024, then tumbled by -1078523800bps in 2025.
  • Quarter analysis of 5 years shows HeartSciences' EBITDA Margin stood at 9011.84% in 2021, then tumbled by -396bps to 44690.53% in 2022, then rose by 10bps to 40254.95% in 2023, then soared by 104bps to 1687.98% in 2024, then tumbled by -5178bps to 85713.23% in 2025.
  • Its last three reported values are 85713.23% in Q4 2025, 98637.84% for Q3 2025, and 1061.86% during Q2 2025.